Գլիկլազիդ (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Գլիկլազիդ" in Armenian language version.

refsWebsite

Global rank Armenian rank

12nih.gov

4^th place

3^rd place

10doi.org

2^nd place

4^th place

5archive.org

6^th place

2web.archive.org

1^st place

1medicines.org.uk

3,823^rd place

1,279^th place

1google.ca

838^th place

113^th place

1thepharmajournal.com

low place

archive.org

British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. էջ 474. ISBN 9780857111562.
Park, J; Kim, KA; Park, PW; Park, CW; Shin, JG (2003). «Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide». Clinical Pharmacology & Therapeutics. 74 (4): 334–40. doi:10.1016/S0009-9236(03)00221-2. PMID 14534520.
Lawrence, C. L.; Proks, P.; Rodrigo, G. C.; Jones, P.; Hayabuchi, Y.; Standen, N. B.; Ashcroft, F. M. (2001). «Gliclazide produces high-affinity block of K ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells». Diabetologia. 44 (8): 1019–25. doi:10.1007/s001250100595. PMID 11484080.
Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor (1990). «Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds». Diabetes Research and Clinical Practice. 8 (2): 109–14. doi:10.1016/0168-8227(90)90020-T. PMID 2106423.
Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang (2007). «Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects». British Journal of Clinical Pharmacology. 64 (1): 67–74. doi:10.1111/j.1365-2125.2007.02846.x. PMC 2000619. PMID 17298483.

doi.org

Schernthaner, G.; Grimaldi, A.; Di Mario, U.; Drzewoski, J.; Kempler, P.; Kvapil, M.; Novials, A.; Rottiers, R.; և այլք: (2004). «GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients». European Journal of Clinical Investigation. 34 (8): 535–42. doi:10.1111/j.1365-2362.2004.01381.x. PMID 15305887.
Park, J; Kim, KA; Park, PW; Park, CW; Shin, JG (2003). «Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide». Clinical Pharmacology & Therapeutics. 74 (4): 334–40. doi:10.1016/S0009-9236(03)00221-2. PMID 14534520.
Lawrence, C. L.; Proks, P.; Rodrigo, G. C.; Jones, P.; Hayabuchi, Y.; Standen, N. B.; Ashcroft, F. M. (2001). «Gliclazide produces high-affinity block of K ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells». Diabetologia. 44 (8): 1019–25. doi:10.1007/s001250100595. PMID 11484080.
Urbanova, J.; և այլք: (2015). «Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a-/- Model». Current Pharmaceutical Design. 21: 5736–5748. doi:10.2174/1381612821666151008124036.
Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor (1990). «Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds». Diabetes Research and Clinical Practice. 8 (2): 109–14. doi:10.1016/0168-8227(90)90020-T. PMID 2106423.
Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; և այլք: (2006). «Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation». Metabolism. 55 (6): 722–30. doi:10.1016/j.metabol.2006.01.019. PMID 16713429.
Elliot, David J.; Lewis, Benjamin C.; Gillam, Elizabeth M. J.; Birkett, Donald J.; Gross, Annette S.; Miners, John O.; Miners, JO (2007). «Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination». British Journal of Clinical Pharmacology. 64 (4): 450–7. doi:10.1111/j.1365-2125.2007.02943.x. PMC 2048545. PMID 17517049.
Rieutord, A; Stupans, I; Shenfield, GM; Gross, AS (1995). «Gliclazide hydroxylation by rat liver microsomes». Xenobiotica. 25 (12): 1345–54. doi:10.3109/00498259509061922. PMID 8719909.
Xu, H; Williams, K M; Liauw, W S; Murray, M; Day, R O; McLachlan, A J (2009). «Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide». British Journal of Pharmacology. 153 (7): 1579–86. doi:10.1038/sj.bjp.0707685. PMC 2437900. PMID 18204476.
Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang (2007). «Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects». British Journal of Clinical Pharmacology. 64 (1): 67–74. doi:10.1111/j.1365-2125.2007.02846.x. PMC 2000619. PMID 17298483.

google.ca

books.google.ca

Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (անգլերեն). John Wiley & Sons. էջ 449. ISBN 9783527607495. Արխիվացված օրիգինալից 2016 թ․ դեկտեմբերի 27-ին.

medicines.org.uk

«Bilxona 30mg Modified-release Tablets - Summary of Product Characteristics (SPC) - (eMC)». www.medicines.org.uk. 2016 թ․ օգոստոսի 29. Արխիվացված օրիգինալից 2016 թ․ դեկտեմբերի 27-ին. Վերցված է 2016 թ․ դեկտեմբերի 27-ին.

nih.gov

pubmed.ncbi.nlm.nih.gov

Schernthaner, G.; Grimaldi, A.; Di Mario, U.; Drzewoski, J.; Kempler, P.; Kvapil, M.; Novials, A.; Rottiers, R.; և այլք: (2004). «GUIDE study: Double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients». European Journal of Clinical Investigation. 34 (8): 535–42. doi:10.1111/j.1365-2362.2004.01381.x. PMID 15305887.
Park, J; Kim, KA; Park, PW; Park, CW; Shin, JG (2003). «Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide». Clinical Pharmacology & Therapeutics. 74 (4): 334–40. doi:10.1016/S0009-9236(03)00221-2. PMID 14534520.
Lawrence, C. L.; Proks, P.; Rodrigo, G. C.; Jones, P.; Hayabuchi, Y.; Standen, N. B.; Ashcroft, F. M. (2001). «Gliclazide produces high-affinity block of K ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells». Diabetologia. 44 (8): 1019–25. doi:10.1007/s001250100595. PMID 11484080.
Ballagi-Pordány, György; Köszeghy, Anna; Koltai, Mária-Zsófia; Aranyi, Zoltán; Pogátsa, Gábor (1990). «Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds». Diabetes Research and Clinical Practice. 8 (2): 109–14. doi:10.1016/0168-8227(90)90020-T. PMID 2106423.
Shimoyama, Tatsuhiro; Yamaguchi, Shinya; Takahashi, Kazuto; Katsuta, Hidenori; Ito, Eisuke; Seki, Hiroyuki; Ushikawa, Kenji; Katahira, Hiroshi; և այլք: (2006). «Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation». Metabolism. 55 (6): 722–30. doi:10.1016/j.metabol.2006.01.019. PMID 16713429.
Elliot, David J.; Lewis, Benjamin C.; Gillam, Elizabeth M. J.; Birkett, Donald J.; Gross, Annette S.; Miners, John O.; Miners, JO (2007). «Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination». British Journal of Clinical Pharmacology. 64 (4): 450–7. doi:10.1111/j.1365-2125.2007.02943.x. PMC 2048545. PMID 17517049.
Rieutord, A; Stupans, I; Shenfield, GM; Gross, AS (1995). «Gliclazide hydroxylation by rat liver microsomes». Xenobiotica. 25 (12): 1345–54. doi:10.3109/00498259509061922. PMID 8719909.
Xu, H; Williams, K M; Liauw, W S; Murray, M; Day, R O; McLachlan, A J (2009). «Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide». British Journal of Pharmacology. 153 (7): 1579–86. doi:10.1038/sj.bjp.0707685. PMC 2437900. PMID 18204476.
Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang (2007). «Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects». British Journal of Clinical Pharmacology. 64 (1): 67–74. doi:10.1111/j.1365-2125.2007.02846.x. PMC 2000619. PMID 17298483.

ncbi.nlm.nih.gov

Elliot, David J.; Lewis, Benjamin C.; Gillam, Elizabeth M. J.; Birkett, Donald J.; Gross, Annette S.; Miners, John O.; Miners, JO (2007). «Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination». British Journal of Clinical Pharmacology. 64 (4): 450–7. doi:10.1111/j.1365-2125.2007.02943.x. PMC 2048545. PMID 17517049.
Xu, H; Williams, K M; Liauw, W S; Murray, M; Day, R O; McLachlan, A J (2009). «Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide». British Journal of Pharmacology. 153 (7): 1579–86. doi:10.1038/sj.bjp.0707685. PMC 2437900. PMID 18204476.
Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang (2007). «Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects». British Journal of Clinical Pharmacology. 64 (1): 67–74. doi:10.1111/j.1365-2125.2007.02846.x. PMC 2000619. PMID 17298483.

thepharmajournal.com

Karmoker J, Priya R, Sarkar S, Islam S (2017). «Comparative in vitro equivalence evaluation of some local Gliclazide brands of Bangladesh» (PDF). The Pharma Innovation Journal. 6: 152–157. Վերցված է 2018 թ․ հունվարի 23-ին.

web.archive.org

«Bilxona 30mg Modified-release Tablets - Summary of Product Characteristics (SPC) - (eMC)». www.medicines.org.uk. 2016 թ․ օգոստոսի 29. Արխիվացված օրիգինալից 2016 թ․ դեկտեմբերի 27-ին. Վերցված է 2016 թ․ դեկտեմբերի 27-ին.
Fischer, Janos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (անգլերեն). John Wiley & Sons. էջ 449. ISBN 9783527607495. Արխիվացված օրիգինալից 2016 թ․ դեկտեմբերի 27-ին.